Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market

Fineline Cube Jul 24, 2026
Company Drug

Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL

Fineline Cube Jul 24, 2026
Company Deals

Zhejiang Huahai Pharmaceutical Co., Ltd Plans Capital Raise for Digital Manufacturing Expansion

Fineline Cube May 20, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a leading Chinese pharmaceutical company, has unveiled plans...

Company Deals

Porton Biologics and SAFE Collaborate to Accelerate Pharmaceutical R&D Services

Fineline Cube May 20, 2024

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Drug

Biotherus Inc. Advances PM8002 Bispecific Antibody to Phase III for Triple Negative Breast Cancer

Fineline Cube May 20, 2024

China’s Biotheus Inc. has announced the initiation of a Phase III clinical study for its...

Company Drug

Jiangsu Hengrui’s Camrelizumab/Apatinib Combo Denied FDA Approval Over Manufacturing Issues

Fineline Cube May 20, 2024

The US Food and Drug Administration (FDA) has issued a complete response letter to Jiangsu...

Company Drug

ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial

Fineline Cube May 20, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...

Company Digital

Siemens Healthineers and Ruijin Hospital Collaborate to Build Medical Digital Human Metaverse

Fineline Cube May 20, 2024

Siemens Healthineers AG, the German medical technology major, has entered into a strategic partnership with...

Company Drug

CSPC Pharmaceutical’s βKlotho Monoclonal Antibody JMT202 Receives Clinical Trial Approval from NMPA

Fineline Cube May 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Roche’s CT-388 Shows Significant Weight Loss in Phase I Clinical Trial for Obesity

Fineline Cube May 20, 2024

Switzerland-based healthcare giant Roche (SWX: ROG) has announced preliminary results from a Phase I study...

Company Deals

Biocytogen Expands Reach to India with GVSAP Partnership for BioMice Models

Fineline Cube May 20, 2024

A recent stock exchange announcement from China-based Biocytogen (HKG: 2315) has highlighted a strategic partnership...

Company

HutchMed Chairman Simon To Steps Down, Dr. Dan Eldar Appointed Successor

Fineline Cube May 20, 2024

HutchMed (NASDAQ: HCM, HKG: 0013) today announced a significant change in leadership with the long-serving...

Company Drug

Eisai to Support Grassroots Healthcare in China with Significant Pariet Donation

Fineline Cube May 20, 2024

Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000...

Company Drug

North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China

Fineline Cube May 17, 2024

North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...

Company Drug

HutchMed’s Sovleplenib Phase III Results to be Showcased at EHA 2024

Fineline Cube May 17, 2024

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013), a biopharmaceutical company based in China, is preparing...

Company Drug

Shanghai UniCAR-Therapy’s Innovative CAR-T Therapy Targets Breakthrough Designation with IL-6 Silencing

Fineline Cube May 17, 2024

Shanghai UniCAR-Therapy Bio-Medicine Technology Co., Ltd, a leading biopharmaceutical company based in China, is on...

Company Deals

Sol-Gel Technologies Partners with Shenzhen Beimei for Twyneo Commercialization in China

Fineline Cube May 17, 2024

Israel-based dermatology specialist Sol-Gel Technologies Ltd. (NASDAQ: SLGL) has announced the signing of a licensing...

Company Deals

J&J Acquires Immune-Mediated Diseases Specialist Proteologix in a Deal Worth Up to USD 850 Million

Fineline Cube May 17, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has announced a deal to...

Policy / Regulatory

China’s Health Commission Boosts Efforts to Monitor and Respond to Drug Shortages

Fineline Cube May 17, 2024

The National Health Commission (NHC) of China has recently announced the reinforcement of national and...

Company Deals

Huaixi Medical and Beijing HumaDX Tech Join Forces to Boost In Vitro Diagnostics

Fineline Cube May 17, 2024

Huaixi Medical, a Nanjing-based specialist in flow cytometry, has entered into a strategic partnership with...

Company Drug

Bayer’s 225Ac-PSMA-Trillium Therapy Begins Early-Stage Clinical Trial for mCRPC

Fineline Cube May 17, 2024

Bayer AG (ETR: BAYN), a multinational pharmaceutical company based in Germany, has this week commenced...

Company Deals

Merck KGaA Subsidiary Teams Up with Aulos Bioscience to Test PD-L1 and Anti-IL-2 Combination

Fineline Cube May 17, 2024

Germany’s Merck KGaA (ETR: MRK) has announced that its Switzerland-based subsidiary, Ares Trading, has entered...

Posts pagination

1 … 392 393 394 … 699

Recent updates

  • Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market
  • Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth
  • Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL
  • Hengrui Pharmaceuticals Secures NMPA First-Line Approval for Camrelizumab-Famitinib Combo in PD-L1-Positive Cervical Cancer
  • Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market

Company

Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth

Company Drug

Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL

Company Drug

Hengrui Pharmaceuticals Secures NMPA First-Line Approval for Camrelizumab-Famitinib Combo in PD-L1-Positive Cervical Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.